Products
Innovative Diabetes Therapies
Amylin successfully launched two first-in-class medicines for the treatment of type 1 and type 2 diabetes.
BYETTA® (exenatide) injection was the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA addresses significant unmet medical needs in type 2 diabetes by providing powerful, sustained A1C reductions with potential weight loss. BYETTA was approved in April 2005 and has been used by more than 1.3 million patients since its introduction.*
Healthcare professionals and people with diabetes may obtain more information, including the complete prescribing information and patient Medication Guide, at www.BYETTA.com.
SYMLIN® (pramlintide acetate) injection is the first and only FDA-approved amylin agonist. It addresses unmet needs of insulin therapy by improving blood glucose control while increasing satiety, which can lead to reduced caloric intake and potential weight loss for people with type 1 or type 2 diabetes who use mealtime insulin. SYMLIN was approved in March 2005 and the SymlinPen® (pramlintide acetate) pen-injector was launched in January 2008—since since its launch more than 130,000 patients have been treated with SYMLIN.
Healthcare professionals and people with diabetes may obtain more information, including the complete prescribing information and the Medication Guide, at www.SYMLIN.com.
About Diabetes
Diabetes affects more than 24 million people in the U.S. and an estimated 285 million adults worldwide.1, 2 Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses.3
According to the Centers for Disease Control and Prevention’s National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.4 In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.5 Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.6,7
References
1 The International Diabetes Federation Diabetes Atlas. Available at: http://www.diabetesatlas.org/content/some-285-million-people-worldwide-will-live-diabetes-2010. Accessed September 21, 2010.
2 Diabetes Statistics. American Diabetes Association. Available at http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed September 21, 2010.
3 Direct and Indirect Costs of Diabetes in the United States. American Diabetes Association. Available at: http://www.diabetes.org/how-to-help/action/resources/cost-of-diabetes.html. Accessed September 21, 2010.
4 Saydah SH, Fradkin J and Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.
5 Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-47.
6 Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2007;30 Suppl 1:S48-65.
7 Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9.
* SDI data, March 2009.